Characteristics of the Coronavirus Disease 2019 and related Therapeutic OptionsArticle Published on 2020-06-242022-10-30 Journal: Molecular Therapy [Category] COVID-19, [키워드] acute respiratory syndrome affecting cause caused Characteristics Clinical symptoms clinical trial coronavirus disease Coronavirus-2 COVID-19 COVID-19 patients death rate Diagnosis effective feature Genome global pandemic Incubation period Infection molecular target option patients Pneumonia potential molecular provide Replication resulting SARS-CoV-2 SARS-COV-2 infection severe health problem suppress target therapeutic drug Treatment Vaccine development [DOI] 10.1016/j.omtm.2020.06.013 PMC 바로가기 [Article Type] Article
Potential Antiviral Options against SARS-CoV-2 InfectionArticle Published on 2020-06-132022-10-28 Journal: Viruses [Category] COVID-19, SARS, [키워드] antiviral drug antiviral drug combinations antivirals broad-spectrum antiviral broad-spectrum antivirals Combination costly disseminate exhibited highest homoharringtonine Infection knowledge monoclonal antibody Neutralization assay option Potential recovered patient Respiratory Coronavirus Salinomycin SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 strain SARS-CoV-2-infected patients screened sera synergy the SARS-CoV-2 time-consuming Treatment treatments of COVID-19 United Nation Vaccines Vero-E6 cell Vero-E6 cells website WHO World Health Organization [DOI] 10.3390/v12060642 PMC 바로가기 [Article Type] Article
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)Article Published on 2020-06-102022-10-28 Journal: Viruses [Category] COVID-19, SARS, [키워드] 25-Hydroxycholesterol acute respiratory syndrome addition AM580 animal model anti-SARS-CoV-2 Anti-SARS-CoV-2 Activity antigen expression Antiviral antiviral activity antiviral agent Antiviral agents caused Chloroquine clinical trials coronavirus COVID-19 evaluated exhibited expression in viral interferon interferons investigated Lipogenesis option pandemic Plaque reduction assay plaque reduction assays Potential Remdesivir Replication SARS-CoV-2 targeting the SARS-CoV-2 Treatment VeroE6 cell Viral antigen viral load reduction viruses [DOI] 10.3390/v12060628 PMC 바로가기 [Article Type] Article
Packed Red Blood Cell Transfusion as a Potential Treatment Option in COVID-19 Patients With Hypoxemic Respiratory Failure: A Case ReportInternal Medicine Published on 2020-06-012022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory distress acute respiratory syndrome addition Administered Asymptomatic Blood Case report caused Cell China Clinical improvement Clinical outcome co-morbidities co-morbidity coronavirus coronavirus disease COVID-19 Critically ill patient critically ill patients drastic effective Evidence help hemoglobin Hypoxemia hypoxia Intubated lung male mild case MOST multiple comorbidities Novel coronavirus option outbreak packed red blood cell transfusion pandemic Patient Poor poor prognosis Potential presenting RBC Red red blood cells report Research respiratory Respiratory failure SARS-CoV-2 syndrome transfusion Treatment strategies [DOI] 10.7759/cureus.8398 PMC 바로가기 [Article Type] Internal Medicine
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?Pharmacology Published on 2020-05-262022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory syndrome addition antiviral activity approved clinical Clinical improvement clinical trial conducted Coronavirus-2 COVID-19 double blind double-blind Ebola Efficacy Evidence exhibited faster global public health globe GS-5734 in vitro in vitro activity in vivo Infection MERS-CoV Novel coronavirus open label option Phase 3 Placebo placebo controlled trial Prevent preventive measure Randomized RdRP Remdesivir RNA RNA polymerase SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 strain Science severe COVID-19 patient statistically significant Strains therapeutic option therapy treat Trial Vaccine WHO Solidarity trial Wuhan, China [DOI] 10.3389/fphar.2020.00791 PMC 바로가기 [Article Type] Pharmacology
Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced CoagulopathyInternal Medicine Published on 2020-05-162022-10-31 Journal: Cureus [Category] COVID-19, [키워드] antagonist Anticoagulant anticoagulation article caused Changing clinical implications clinical settings Coagulopathy Community Complication coronavirus disease COVID-19 COVID-19 patients D-dimer demonstrated direct-acting DOAC dose early stage Efficacy fibrinogen Hospitalization hospitalized patients Japan less LMWH low molecular weight heparin management nafamostat New option outcome Outpatient pandemic Patient Platelet count prophylactic dose raising Research respond Scientific community severe complication Society the disease therapeutic dose therapy unfractionated heparin VKA [DOI] 10.7759/cureus.8150 PMC 바로가기 [Article Type] Internal Medicine
Therapeutic Options for Coronavirus Disease 2019 (COVID-19) – Modulation of Type I Interferon Response as a Promising Strategy?Public Health Published on 2020-05-152022-10-31 Journal: Frontiers in Public Health [Category] COVID-19, MERS, SARS, [키워드] Azithromycin COVID-19 Hydroxychloroquine option response SARS-CoV-2 Type type I interferon [DOI] 10.3389/fpubh.2020.00185 PMC 바로가기 [Article Type] Public Health
Alternative Care Sites: An Option in DisastersEndemic Infections Published on 2020-05-132022-10-28 Journal: Western Journal of Emergency Medicine [Category] Coronavirus, SARS, [키워드] administration Care Community COVID-19 pandemic criteria Developing disaster equipment Healthcare system Local magnitude occur option Situated structures variety [DOI] 10.5811/westjem.2020.4.47552 PMC 바로가기 [Article Type] Endemic Infections
Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory TherapyCardiovascular Medicine Published on 2020-04-302022-10-31 Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19, [키워드] addition Algorithm Anti-inflammatory therapy cardiovascular cardiovascular anti-inflammatory therapy cardiovascular disease cardiovascular diseases cardiovascular impairment caused China clinical trial clinical trials Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients current Cytokine storm Direct Drug screening Efficacy and safety ENhance feature global pandemic high risk IL-1β IL-6 impairment in vitro Inflammation Inflammatory learning management mechanism mitigate MODS multiple organ dysfunction occurred option outcomes pathway positive preclinical study proceed profiles Prognosis Protective reduce SARS-CoV-2 Severe case syndrome Th1 Th2 response TNF-α translation Treatment treatments of COVID-19 viral infection [DOI] 10.3389/fcvm.2020.00078 PMC 바로가기 [Article Type] Cardiovascular Medicine
Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?Microbiology Published on 2020-04-302022-10-31 Journal: Frontiers in Microbiology [Category] COVID-19, [키워드] Antiviral treatment channel endo-lysosomal dysfunction flavonoid inhibition naringenin natural option SARS - CoV SARS-CoV-2 therapeutic targets two-pore channel (TPC) [DOI] 10.3389/fmicb.2020.00970 PMC 바로가기 [Article Type] Microbiology